Calendario›ELOX›ELX-02

ELX-02

A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X Allele

Ensayo de Eloxx Pharmaceuticals, Inc. en Fibrosis quistica.

Más ensayos de: Fibrosis quística.

Fase

Fase 2

Estado

Completado

Participantes

17

previstos

Centros

10

Fin del objetivo primario

oct 2022

fecha real

Qué significa cada fase y cada estado.

Estudio de intervención, de un solo grupo, abierto. Comenzó en nov 2019.

Qué mide

AEs associated with different dose levels of ELX-02 (From the time of first dosing through the follow-up visit, an average of approximately 9 weeks) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis is a Phase 2 open-label, dose-escalation study to evaluate the safety, tolerability, PK, and PD of multiple dose levels of SC administered ELX-02 with and without ivacaftor in patients with CF with at least one G542X allele. In total, up to 16 patients will be enrolled in the trial; up to 4 patients will be homozygotes for G542X, and the remaining patients will be compound heterozygotes with one G542X or phenotypically similar nonsense allele and any Class 1 or Class 2 mutation. Each patient will receive up to 5 escalating doses as follows: * ELX-02 0.3 mg/kg per day SC * ELX-02 0.75 mg/kg per day SC * ELX-02 1.5 mg/kg per day SC * An individualized dose of ELX-02, as high as 3.0 mg/kg per day SC, based on the patients observed safety and tolerability, PK at previous doses and the results of laboratory tests. * ELX-02 1.5 mg/kg per day SC plus 150 mg ivacaftor every 12 bid

Más ensayos de ELOX

Todos los de ELOX, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT04135495), actualizada en nov 2022.